Prescription drug use and expenditures among dually eligible beneficiaries

Health Care Financing Review

Volumn 28, Issue 4, 2007, Pages 43-56

  Bagchi, Ann D ^a   Esposito, Dominick ^a   Verdier, James M ^a  

^a MATHEMATICA POLICY RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; CALCIUM CHANNEL BLOCKING AGENT; GENERIC DRUG; NARCOTIC ANALGESIC AGENT; NEUROLEPTIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT;

AGED; ARTICLE; COST CONTROL; DISABLED PERSON; DRUG COST; DRUG UTILIZATION; LAW; MANAGED CARE; MEDICAID; MEDICARE; NURSING HOME PATIENT; PRESCRIPTION; UNITED STATES;

AGED; DATABASES, FACTUAL; ELIGIBILITY DETERMINATION; FEMALE; HEALTH EXPENDITURES; HUMANS; MALE; MEDICAID; MEDICARE; MIDDLE AGED; PRESCRIPTIONS, DRUG; UNITED STATES;

EID: 34547443013     PISSN: 01958631     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Berndt, E.R.: Trends and Drivers of Expenditures on Psychotropic Drugs in the U.S. Presented at the NIMH Workshop on Pharmacoeconomics. Washington, DC. May 2003.
2. Binder, C., Gross, L., Gross, D., et al.: Trends in Manufacturer Prices of Prescription Drugs Used by Older Americans. AARP. Washington, DC. June 2006.
3. Briesacher, B.A., Limcangco, R., Simoni-Wastila, L., et al.: The Quality of Antipsychotic Drug Prescribing in Nursing Homes. Archives of Internal Medicine 165:1280-1285, June 2005.
4. Buck, J.A.: Psychotropic Drug Practice in Nursing Homes. Journal of the American Geriatrics Society 36(5):409-418, May 1988.
5. Centers for Medicare & Medicaid Services: Medicaid Analytic eXtract (MAX) General Information. 2006. Internet address: http://http://www.cms.hhs.gov/MedicaidDataSourcesGenInfo/07_ MAXGeneralInformation.asp (Accessed 2007.)
6. Dale, S.B. and Verdier, J.M.: State Medicaid Prescription Drug Expenditures for Medicare-Medicaid Dual Eligibles. The Commonwealth Fund. New York, NY. April 2003.
7. Elam, L., Bruen, B., and Tilly, J.: Medicaid and the Prescription Drug Benefit: Cost Containment Strategies and State Experiences. Kaiser Commission on Medicaid and the Uninsured. Washington, DC. September 2002.
8. Frank, R.G., Conti, R.M., and Goldman, H.H.: Mental Health Policy and Psychotropic Drugs. The Milbank Quarterly 83(2):271-298, 2005.
9. Gurvich, T. and Cunningham, J.A.: Appropriate Use of Psychotropic Drugs in Nursing Homes. American Family Physician 61:1437-1446, March 2000.
10. Holahan, J. and Ghosh, A.: Dual Eligibles: Medicaid Enrollment and Spending for Medicare Beneficiaries in 2003. The Henry J. Kaiser Family Foundation. Washington, DC. July 2005.
11. Huskamp, H.A. and Keating, N.L.: The New Medicare Drug Benefit: Formularies and Their Potential Effects on Access to Medications. Journal of General Internal Medicine 20(7):662-665, July 2005.
12. Kaiser Commission on Medicaid and the Uninsured. Dual Eligibles and Medicare Part D. The Henry J. Kaiser Family Foundation. Washington, DC. 2006.
13. Kasper, J., Elias, R., and Lyons, B.: Dual Eligibles: Medicaid's Role in Filling Medicare's Gaps. March 2004. Internet address: http://www.kff.org/medicaid/7058.cfm (Accessed 2007.)
14. Koyanagi, C., Forquer, S., and Alfano, E.: Medicaid Policies to Contain Psychiatric Drug Costs. Health Affairs 24(2):536-544, March/April 2005.
15. Medicare Payment Advisory Commission: Report to the Congress: New Approaches to Medicare. Washington, DC. 2004.
16. Moran, M.: Part D Plans May be Startled by Drug Costs for Dual Eligibles. Psychiatric News 40(18):18, September 2005.
17. Morden, N.E. and Garrison, Jr., L.P.: Implications of Part D for Mentally Ill Dual Eligibles: A Challenge for Medicare. Health Affairs 25(2):491-500, March/ April 2006.
18. Morden, N.E. and Sullivan, S.D.: States' Control of Prescription Drug Spending: A Heterogeneous Approach. Health Affairs 24(4):1032-1038, July/ August 2005.
19. National Pharmaceutical Council.: Pharmaceutical Benefits Under State Medical Assistance Programs, 2001. Washington, DC. 2002.
20. Ray, W.A., Federspiel, C.F., and Schaffner, W.A.: A Study of Antipsychotic Drug Use in Nursing Homes: Epidemiologic Evidence Suggesting Misuse. American Journal of Public Health 70:485-491, May 1980.
21. Stuart, B. and Singhal, P.: The Stability of Medicaid Coverage for Low-Income Dually Eligible Medicare Beneficiaries. The Henry J. Kaiser Family Foundation. Washington, DC. 2006.
22. Stuart, B., Shea, D., and Briesacher, B.: Dynamics in Drug Coverage of Medicare Beneficiaries: Finders, Losers, Switchers. Health Affairs 20(2):86-99, March/April 2001.
23. Verdier, J. and Kim, M.: Medicaid Drug Use Data Show High Costs and Wide Variation for Dual Eligibles. Princeton, NJ. Mathematica Policy Research, Inc. 2005.
24. Wrobel, M.V., Doshi, J., Stuart, B.C., et al.: Predictability of Prescription Drug Expenditures for Medicare Beneficiaries. Health Care Financing Review 25(2):37-46, Winter 2003-2004.
25. Zhao, Y., Ash, A.S., Ellis, R.P., et al.: Predicting Pharmacy Costs and Other Medical Costs Using Diagnoses and Drug Claims. Medical Care 43(1):34-43, January 2005.